294 related articles for article (PubMed ID: 33338321)
1. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
3. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
Shi B; Qi J
J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
[TBL] [Abstract][Full Text] [Related]
5. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
6. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
7. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
8. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
[TBL] [Abstract][Full Text] [Related]
9. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
11. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
Li S; Gao J; Xu Q; Zhang X; Huang M; Dai X; Huang K; Liu L
Front Immunol; 2021; 12():693314. PubMed ID: 34177954
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications.
Zhou YJ; Zhu GQ; Lu XF; Zheng KI; Wang QW; Chen JN; Zhang QW; Yan FR; Li XB
Cancer Immunol Immunother; 2020 Jun; 69(6):1057-1069. PubMed ID: 32100076
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.
Zheng X; Li L; Yu C; Yang J; Zhao Y; Su C; Yu J; Xu M
Aging (Albany NY); 2021 Nov; 13(21):24313-24338. PubMed ID: 34762599
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
Front Immunol; 2021; 12():735170. PubMed ID: 34531875
[TBL] [Abstract][Full Text] [Related]
16. Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule.
Yang L; Lv Y; Wang S; Zhang Q; Pan Y; Su D; Lu Q; Zuo Y
Genomics; 2020 Mar; 112(2):1500-1515. PubMed ID: 31472243
[TBL] [Abstract][Full Text] [Related]
17. Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures.
Wang T; Li T; Li B; Zhao J; Li Z; Sun M; Li Y; Zhao Y; Zhao S; He W; Guo X; Ge R; Wang L; Ding D; Liu S; Min S; Zhang X
Front Immunol; 2022; 13():805184. PubMed ID: 35154121
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy.
Zheng X; Gao Y; Yu C; Fan G; Li P; Zhang M; Yu J; Xu M
Sci Rep; 2021 Sep; 11(1):19432. PubMed ID: 34593914
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
20. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
